"Founded by Dr. Craig Walker in 1983, Cardiovascular Institute of the South (CIS) is a world-leader in preventing, detecting and treating cardiovascular and peripheral vascular disease. CIS has earned international acclaim as a pioneer of research, development and education, as well as an innovator in the treatment of peripheral vascular disease. Schedule an appointment with one of our expert cardiologists in Houma today."

During the past decade, Cardiovascular Institute of the South conducted 48 clinical trials. In the 10-year time frame, 48 clinical trials started and 15 clinical trials were completed, i.e. on average, 31.3% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 11 clinical trials were completed. i.e. 61.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Cardiovascular Institute of the South" #1 sponsor was "Abbott Medical Devices" with 6 trials, followed by "Boston Scientific Corporation" with 4 trials sponsored, "CVRx, Inc." with 4 trials sponsored, "Ancora Heart, Inc." with 3 trials sponsored and "Horizons International Peripheral Group" with 3 trials sponsored. Other sponsors include 43 different institutions and companies that sponsored additional 45 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Cardiovascular Institute of the South" #1 collaborator was "Advanced Catheter Therapies, Inc." with 2 trials as a collaborator, "Gilead Sciences" with 2 trials as a collaborator, "Baim Institute for Clinical Research" with 1 trials as a collaborator, "Cardiovascular Research Foundation, New York" with 1 trials as a collaborator and "ClinLogix. LLC" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Cardiovascular Institute of the South" are "Heart Failure" (12 trials), "Peripheral Arterial Disease" (12 trials), "Atrial Fibrillation" (7 trials), "Peripheral Vascular Disease" (4 trials) and "Coronary Artery Disease" (3 trials). Many other conditions were trialed in "Cardiovascular Institute of the South" in a lesser frequency.

Most popular intervention types in "Cardiovascular Institute of the South" are "Device" (49 trials), "Drug" (17 trials), "Other" (6 trials), "Procedure" (5 trials) and "Combination Product" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Ranolazine" (3 trials), "Azimilide Dihydrochloride" (2 trials), "BAROSTIM NEO® System" (2 trials) and "LARIAT + PVI" (2 trials). Other intervention names were less common.

The vast majority of trials in "Cardiovascular Institute of the South" are 68 trials for "All" genders.

Currently, there are NaN active trials in "Cardiovascular Institute of the South". undefined are not yet recruiting, 13 are recruiting, 15 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 25 completed trials in Cardiovascular Institute of the South, 2 suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Cardiovascular Institute of the South, 2 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 41 trials that are defined as “Not Applicable".

Cardiovascular Institute of the South has several departments that took part in Clinical trials: "Cardiovascular Institute of the South" - 2 trials